{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:00:49Z","timestamp":1757311249410,"version":"3.37.3"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Celltrion Healthcare Co., Ltd.","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The introduction of biological disease-modifying anti-rheumatic drugs into clinical practice has dramatically improved the clinical outcomes of individuals with rheumatoid arthritis (RA). We are conducting the IFX-SIRIUS STUDY I that evaluates whether switching from originator infliximab (IFX) to its biosimilar, CT-P13, is not inferior in maintaining nonclinical relapse to continue treatment with originator IFX in patients with RA achieving clinical remission. It is the next great issue whether disease activity can be maintained in good condition after discontinuation of CT-P13 because no evidence is available regarding the clinical value of discontinuing biosimilars in patients with RA. Thus, we will evaluate whether a condition without clinical relapse will be maintained after discontinuation of CT-P13 in patients with RA, achieving clinical remission or low disease activity during the IFX-SIRIUS STUDY I.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design:<\/jats:title>\n            <jats:p>This study is an interventional, multicenter, open-label, single-arm clinical trial with a 48-week follow-up. Patients with RA who are treated with CT-P13 and sustained nonclinical relapse during the IFX-SIRIUS STUDY I will be included. Patients will discontinue CT-P13 after the study period of the IFX-SIRIUS STUDY I. We will evaluate disease activity by clinical disease activity indices and musculoskeletal ultrasound (MSUS). The primary endpoint is the proportion of patients who do not have clinical relapse during the study period. Important secondary endpoints are the changes from the baseline of the MSUS scores. We will also comprehensively analyze the serum levels of multiple biomarkers, such as cytokines and chemokines. In addition, if a clinical relapse occurs in patients after the discontinuation of CT-P13, we will evaluate the effectiveness and safety of restarting CT-P13.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>The study results are expected to show the clinical benefit of the discontinuation of CT-P13 and effectiveness and safety of restarting CT-P13 after clinical relapse. The strength of this study is to prospectively evaluate the therapeutic effectiveness by not only clinical disease activity indices but also standardized MSUS findings in multiple centers. We will explore whether parameters at baseline can predict a nonclinical relapse after the discontinuation of CT-P13 by integrating multilateral assessments, that is, patient's characteristics, clinical disease activity indices, MSUS findings, and serum biomarkers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This study was registered in the Japan Registry of Clinical Trials (https:\/\/jrct.niph.go.jp) on April 20, 2020 as jRCTs071200007.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021480","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T20:01:41Z","timestamp":1596571301000},"page":"e21480","source":"Crossref","is-referenced-by-count":1,"title":["Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II)"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-2039","authenticated-orcid":false,"given":"Toshimasa","family":"Shimizu","sequence":"first","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"},{"name":"Departments of Immunology and Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ya","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Departments of Immunology and Rheumatology"},{"name":"Community Medicine and, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuri","family":"Minoda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"},{"name":"Departments of Immunology and Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Departments of Immunology and Rheumatology"},{"name":"Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","article-title":"Biologic discontinuation studies: a systematic review of methods","volume":"73","author":"Yoshida","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2007.078451","article-title":"Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology","volume":"67","author":"Torp-Pedersen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e000237","DOI":"10.1136\/rmdopen-2015-000237","article-title":"Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study","volume":"2","author":"D\u2019Agostino","year":"2016","journal-title":"RMD Open"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: Reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"key":"R14-20230915","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.autrev.2012.11.009","article-title":"Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?","volume":"12","author":"Modena","year":"2013","journal-title":"Autoimmun Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:43:18Z","timestamp":1694824998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021480"}},"subtitle":["Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments"],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":16,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021480","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,8,7]]}}}